Results 251 to 260 of about 51,902 (295)
Emerging role of Janus kinase inhibitors in ulcerative colitis management. [PDF]
Ahsan MU +5 more
europepmc +1 more source
Journal of the European Academy of Dermatology and Venereology, EarlyView.
Albert Wolkerstorfer +10 more
wiley +1 more source
Janus kinases in immune cell signaling [PDF]
Summary: The Janus family kinases (Jaks), Jak1, Jak2, Jak3, and Tyk2, form one subgroup of the non‐receptor protein tyrosine kinases. They are involved in cell growth, survival, development, and differentiation of a variety of cells but are critically important for immune cells and hematopoietic cells.
Kamran Ghoreschi +2 more
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Negative Regulation of Janus Kinases
Cell Biochemistry and Biophysics, 2001The precise regulation of both the magnitude and the duration of Janus kinase (JAK) catalytic activity is essential for the cytokine orchestration of many biological processes, and the dysregulation of JAK activity has pathological implications.
R J, Duhé, L H, Wang, W L, Farrar
openaire +2 more sources
Malignancy and Janus Kinase Inhibition
Rheumatic Disease Clinics of North America, 2017The use of biologics such as anti-tumor necrosis factor and oral Janus kinase inhibitors have revolutionized the treatment of rheumatoid arthritis (RA). The risk of malignancies such as lymphomas, lung cancer, and nonmelanoma skin cancers (NMSCs) is greater in patients with RA compared with the general population.
Padmapriya, Sivaraman, Stanley B, Cohen
openaire +2 more sources
The many faces of Janus kinase
Biochemical Pharmacology, 2012Janus kinases have proved to be essential for many immunological processes but there is growing evidence that they also play a critical role in pathogenesis of many diseases including inflammatory diseases and cancer where they promote multiple steps of tumorigenesis.
Matthew M, Seavey, Pawel, Dobrzanski
openaire +2 more sources
Seminars in Oncology, 2009
The chronic myeloproliferative neoplasms (MPNs) polycythemia vera (PV), essential thrombocytosis (ET), and primary myelofibrosis (MF) are commonly associated with mutations in the Janus kinase gene JAK2. A hallmark of PV is an abundance of red blood cells; ET, too many platelets; and MF, accumulation of neutrophils and monocytes accompanied by bone ...
openaire +2 more sources
The chronic myeloproliferative neoplasms (MPNs) polycythemia vera (PV), essential thrombocytosis (ET), and primary myelofibrosis (MF) are commonly associated with mutations in the Janus kinase gene JAK2. A hallmark of PV is an abundance of red blood cells; ET, too many platelets; and MF, accumulation of neutrophils and monocytes accompanied by bone ...
openaire +2 more sources
Janus kinases in cytokine signalling
Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences, 1996Abstract Hematopoiesis is largely regulated by the binding of cytokines to receptors of the cytokine receptor superfamily. Although lacking catalytic domains, members of the cytokine receptor superfamily mediate ligand dependent activation of tyrosine phosphorylation which is critical for all receptor functions.
James N. Ihle, Christopher John Marshall
openaire +2 more sources
Investigational Janus kinase inhibitors
Expert Opinion on Investigational Drugs, 2013Dysregulation of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway is central to the pathophysiology of myeloproliferative neoplasms (MPN). Small molecule inhibitors of JAK family members are currently under investigation for the treatment of MPN.
Constantine S, Tam, Srdan, Verstovsek
openaire +2 more sources
Mapping the kinase domain of janus kinase 3
Bioorganic & Medicinal Chemistry Letters, 2003The utilization and impact of parallel synthesis on lead exploration around initial hit oxindole (1) are described. The emergent SAR, analogue design and functional impact will also be detailed.
Christopher, Adams +24 more
openaire +2 more sources

